Partnering Strategy

The SciFluor pipeline contains novel and differentiated small molecule compounds in a wide range of disease therapeutic categories, including ophthalmology, fibrosis and neurology. We have an extensive and expanding patent estate covering our drug candidates and methods of their use. The company's business strategy focuses on establishing collaborative partnerships to drive these new chemical entities through development and commercialization to address unmet clinical and commercial needs.

Contact:
Scott Edwards, Ph.D.
scott.edwards@scifluor.com | Info@Scifluor.com

SciFluor News

SciFluor Announces Appointment of Robert Dempsey to Board of Directors
read more >

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >